Trump sues BBC for $10 bln over documentary on 2021 Capitol riots
Investing.com - Cantor Fitzgerald has reiterated an Overweight rating on Aclaris Therapeutics (NASDAQ:ACRS), highlighting the company’s strong catalyst path for 2026 and attractive risk/reward profile. According to InvestingPro data, analysts maintain a strong Buy consensus with price targets ranging from $2 to $16, suggesting significant upside potential from current levels.
The research firm pointed to upcoming clinical milestones including Phase 1 proof-of-concept readouts for the company’s TSLP/IL-4 bispecific in atopic dermatitis and asthma, as well as Phase 2B atopic dermatitis results for its TSLP antibody.
Cantor Fitzgerald described the TSLP/IL-4 bispecific as a "potentially game-changing asset" that demonstrates strong drug properties including potency and half-life, along with promising preclinical data that positions it well against competitors.
The firm noted that even Phase 1 MAD data for the TSLP bispecific expected early next year could move the stock if immunogenicity data looks favorable, given that the TSLP and IL-4 targets are well-validated in the industry.
Aclaris currently has a market capitalization of approximately $200 million with $180 million in cash, providing runway into the second half of 2028, according to Cantor Fitzgerald’s analysis. InvestingPro data confirms the company’s strong liquidity position with a current ratio of 3.88 and more cash than debt on its balance sheet. Get access to the full financial health analysis and 10+ additional ProTips with an InvestingPro subscription.
In other recent news, Aclaris Therapeutics, Inc. announced positive top-line results from its Phase 2a trial of ATI-2138, aimed at treating moderate-to-severe atopic dermatitis. The trial, which involved 14 patients receiving low doses of the drug, demonstrated a favorable tolerability profile and clinically meaningful improvements in disease severity measures. The study met its primary safety endpoint, with no severe adverse events or treatment-emergent adverse events reported, according to the company’s press release. Additionally, Aclaris will present further data from this trial at the upcoming European Academy of Dermatology and Venereology Congress in Paris. Dr. Jessica Beaziz-Tordjman will deliver the presentation, highlighting the molecular and clinical effects of ATI-2138. These developments provide further insight into the potential of Aclaris’ treatment for atopic dermatitis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.